SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid fears of Middle East supply disruptions, especially attacks and threats affecting shipping around the Strait of Hormuz, alongside risks to oil infrastructure. Traders are split between viewing the supply concerns as support for further gains and expecting a pullback if tensions ease or the rally fades.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Discussion is dominated by GameStops warrants nearing expiration, with the shares below the exercise price and holders debating whether the warrants will expire worthless. Bears criticize Cohen and doubt an extension or catalyst will arrive, while bulls speculate he may take action; some also view unused warrants as avoiding dilution.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound in the Nasdaq has sparked volatile trading, with traders debating whether the sharp bounce can hold or is a bull trap. AI infrastructure spending and debt concerns, rising oil prices, and upcoming megacap earnings are keeping sentiment divided.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and higher-rate concerns have weighed on rate-sensitive small caps, with traders highlighting IWMs technical weakness and heavy demand for puts. The community is split between expecting an oversold bounce or rotation into small caps and anticipating further declines if support fails.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders citing the analyst price-target cut, IPO lockup share releases and concerns about insider selling, alongside broader weakness in AI hardware. Bulls see an oversold opportunity and point to its wafer-scale technology, while bears question its valuation, ability to scale and reliance on OpenAI.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms weak share performance is drawing attention amid a broader semiconductor selloff and concerns about AI spending, financing, and returns; many traders also say CEO Hock Tans casino remarks worsened sentiment. The 10-year NTT DOCOMO VMware agreement is cited as positive news, but traders disagree on whether the deal or strong AI-growth expectations can offset the sector and valuation concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp AI-infrastructure selloff and a volatile rebound, with traders debating whether the bounce can hold or is another bull trap. Concerns about neocloud financing needs and cash flowespecially amid sector-wide debt worriescompete with confidence that long-term demand for AI compute remains strong.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas equity offering to fund expansion has been a major focus, with traders debating the dilution and the sharp, volatile pullback it accompanied. That concern contrasts with bullish views that AI data-center and networking demand, raised guidance, and expected earnings growth support buying the dip.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its upcoming earnings report, as traders weigh the results and guidance against a sharp pullback in semiconductor equipment stocks. Some see the dip as oversold and are looking for a support bounce, while others remain cautious about further selling and earnings volatility.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is drawing attention after a sharp selloff alongside enterprise hardware peers, with traders pointing to Barclays downgrade and concerns that AI spending has not yet produced a meaningful growth inflection, while higher memory costs may also temper upside. The community is split between viewing the drop as an overreaction and buying opportunity and worrying that the stock may remain under pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did KPRX Stock Surge 17% Pre-Market Today?

Equity

The company announced a $24 million private placement, led by Perceptive Advisors and ADAR1 Capital Management.

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting...

Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know

Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Reported GAAP EPS of -$0.34 up 37.04% YoY

Kiora Pharmaceuticals continues to incur net losses while facing clinical trial execution risks and dependence on the successful completion of strategic transactions to secure additional capital for future operational needs.

Kiora Pharmaceuticals strengthened its financial position with a $24.0 million private placement, extending its operating runway into late 2028 while advancing clinical trials for KIO-301 with fully reimbursed development costs.

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Kiora Pharmaceuticals Inc

Neutral Sentiment

<ul class="summary-bullets"><li>The financing includes $5 million in upfront proceeds and $19 million tied to the exercise of warrants.</li><li>Funds will be used to support general operations, business development, and ongoing research and development, the company said.</li><li>Recently, Kiora’s trial to treat retinitis pigmentosa entered the patient dosing phase.</li></ul>Shares of Kiora Pharmaceuticals, Inc. (KPRX) jumped more than 17% in pre-market trading on Tuesday after the company unveiled a $24 million private placement deal, signaling fresh support for its ongoing eye disease treatment pipeline.If the premarket levels hold after the opening bell, <a href="https://stocktwits.com/symbol/KPRX">KPRX shares</a> would trade at their highest levels in more than two months.<h2 class="st-heading-2">KPRX To Receive $5 Million Upfront</h2>The financing includes $5 million in upfront proceeds, with an additional $19 million tied to the potential exercise of milestone-based warrants. The investment was led by Perceptive Advisors and ADAR1 Capital Management.The offering was priced at-the-market, with each share and prefunded warrant sold together at $2.543. These include short-term Tranche A-1 warrants and longer-term Tranche A-2 warrants, both exercisable at $1.94 per share. The Tranche A-2 warrants are valid for up to four years, but their term shortens to 30 days once any of Kiora completes enrolment in a Phase 3 trial.KPRX stock closed at $2.02 on Monday.Kiora said it plans to use the initial funds to support general operations, business development, and ongoing research and development.Recently, Kiora advanced its pipeline with KIO-301 entering patient dosing in the Phase 2 ABACUS-2 trial for retinitis pigmentosa, a rare disease that causes retinal degeneration.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.Chatter was mixed, with one user calling the placement “solid news.”<stembedurl>https://stocktwits.com/The_Assassin/message/649554703</stembedurl>Another user expects the stock to fall below $1 by the end of the week.<stembedurl>https://stocktwits.com/Shortski/message/649556539</stembedurl>Year-to-date, the stock has climbed by around 2%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

Kiora Pharmaceuticals (KPRX) - The company announced a $24 million private placement, led by Perceptive Advisors and ADAR1 Capital Management.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$2.38
Prev Close	$2.40
Open	$2.37
Dividend Yield	0.00%
50-Day Moving Average	$2.58
Beta	0.76
Avg. Volume	13,456.54
PE Ratio	-0.90

52-Week High	$2.91
52-Week Low	$1.76
Market Capitalization	$10.62M
EPS (Annual)	-$2.60
Price to Book	0.63
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

KPRX Fundamentals